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Abstract 
Despite accumulating evidence demonstrating strong epidemiological and mechanistic 
associations between cigarette smoking, hyperglycemia, and the development of type 2 
diabetes, tobacco abuse has not been uniformly recognized as a modifiable risk factor 
in diabetes prevention or screening strategies. In this review, we highlight population-
based studies that have linked cigarette smoking with an increased risk of type 2 
diabetes and summarize clinical and preclinical studies offering insight into mechanisms 
through which cigarette smoking and nicotine exposure impact body composition, 
insulin sensitivity, and pancreatic β cell function.  Key questions for future studies are 
identified and strategies for smoking cessation as a means to decrease diabetes risk 
are discussed.   
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Introduction 
 
Worldwide, diabetes mellitus affects nearly 422 million individuals and is directly 
responsible for 1.5 million deaths while indirectly contributing to an additional 17.5 
million deaths each year [1].  Type 2 diabetes (T2D) accounts for 90-95% of diabetes 
cases and is caused by insulin resistance and progressive loss of β cell function and 
mass.  Because T2D risk is strongly linked to environmental, nutritional, and lifestyle 
determinants, targeting known risk factors through early lifestyle modification remains 
the most effective strategy for decreasing disease prevalence and mortality [1]. 
According to the 2014 Surgeon General’s Report, smoking increases the risk of T2D by 
30-40% for active smokers compared to non-smokers, suggesting that smoking 
cessation should be emphasized as an essential public health strategy to combat the 
global epidemic of diabetes [2].  The World Health Organization recognizes smoking as 
a preventable risk factor for T2D and endorses smoking avoidance/cessasion as part of 
their lifestyle recommendations [3].  However, both the American Diabetes Association 
and the International Diabetes Foundation do not currently include smoking as a 
modifiable risk factor for diabetes development or consider smoking status as factor that 
should prompt diabetes screening [4, 5].  In this review, we highlight key population-
based studies that have linked cigarette smoking with an increased risk of T2D and 
summarize clinical and preclinical studies that provide insight into the mechanisms 
through which cigarette smoking impacts metabolic health and glucose homeostasis. 
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Epidemiological evidence linking cigarette smoking and diabetes 
A variety of epidemiological studies have demonstrated associations between 
cigarette smoking and the development of T2D [6-8].  The Health Professionals’ Follow-
Up Study analyzed data from over 40,000 American male health care professionals who 
were followed with biannual surveys for over six years from 1986-1992.  In this study, 
men who smoked 25 or more cigarettes per day had a relative risk of incident diabetes 
of 1.94 (95% confidence interval (CI) 1.25, 3.03) compared to non-smokers [8]. Similar 
results have been shown in other ethnic groups, including a study of nearly 50,000 
Chinese men who were followed on average for 5.4 years.  In this cohort, those who 
smoked more than 20 cigarettes per day had an elevated hazard ratio of incident T2D of 
1.25 (95% CI: 1.00, 1.56), while men with a ≥ 40 pack-year history of smoking had an 
elevated hazard of T2D of 1.28 (95%CI: 1.04, 1.57) [9]. In a study of U.S. 
postmenopausal females, those who smoked on average 16.2 cigarettes per day 
exhibited a 1.28-fold increased risk of new diabetes (95% CI: 1.20, 1.36). Risk was 
mitigated in those who stopped smoking; after 10 years of cessation, the risk of 
diabetes became equivalent to that of never-smokers [10]. A similar analysis was 
performed in a Korean cohort of 1,236,443 men and women who were aged 30-95 
years at baseline and followed prospectively over 14 years.  Smoking was associated 
with an increased risk for diabetes treatment, hospitalization, and mortality among both 
men and women, and risk increased in a dose-dependent manner with the number of 
cigarettes smoked per day.  Interestingly, data from this cohort also suggested an 
increased risk for men compared to women [11].  
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Studies have also examined associations between smoking and glycemia.  In a 
large cross-sectional study of 2704 men and 3385 women followed in the European 
Investigation into Cancer (EPIC-Norfolk) study, cigarette smoking was independently 
associated with higher hemoglobin A1c (HbA1c) concentrations, with both male and 
female smokers exhibiting similar changes in HbA1c values.  This analysis 
demonstrated that HbA1C rose by 0.12% per 20 pack-years of smoking in participants 
of both genders [12]. Similarly, data from the National Health and Nutrition Examination 
survey, which included 17,287 adults without diabetes, showed that the mean age-
adjusted HbA1C was higher in patients with elevated circulating levels of the nicotine 
metabolite, cotinine, while smokers exhibited a 7% increase in HbA1c compared to 
those who had never smoked [13].  
 
Smoking Leads to a Variety of Chemical Exposures 
 Cigarettes and other smoking products contain a mix of chemical additives with 
the potential to impact metabolic health. Nicotine is one of the major bioactive 
substances in cigarettes and is among the most widely consumed additive.  Nicotine is 
an alkaloid naturally produced by the tobacco plant that binds nicotinic acetylcholine 
receptors, found throughout neuronal and non-neuronal or visceral organs.  These 
receptors participate in signaling within the central and peripheral nervous system and 
in a number of metabolic tissues, including pancreatic islets, adipose tissue, 
macrophages, liver, and skeletal muscle [14-17].  Nicotine has been shown to directly 
alter glucose homeostasis [18], suggesting an important role for this additive in the 
development of T2D.  Cigarette smoking also results in increased blood serum levels of 
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heavy metals such as lead, arsenic, and cadmium [19]. However, studies of the impact 
of these substances on glucose homeostasis have yielded somewhat inconsistent 
results. For instance, exposure to low environmental levels of inorganic arsenic in 3602 
Korean adults increased the prevalence of diabetes. Additionally, glucose tolerance was 
inversely correlated with urinary arsenic levels, suggesting a role for the heavy metal in 
the development of diabetes [20]. In a Bangladeshi study, the odds ratio of diabetes 
was 8.83 in male smokers with arsenic blood serum levels of ≥15.5 µg/L compared to 
male smokers with lower arsenic levels [21]. Likewise, participants from the Canadian 
Health Measures survey with high urinary arsenic levels (≥22.99 µg/L) showed a nearly 
2-fold increased risk of T2D compared to those with urinary arsenic levels of less than 
5.71 µg/L [22].  In contrast, no significant relationship was found between levels of lead, 
mercury, or cadmium, and diabetes or measures of β cell function in another study of 
Korean men and women, even when considering the sum exposure of heavy metals 
[23].  Likewise, only limited data could support an association between arsenic and 
diabetes in chronically exposed populations in Taiwan and Bangladesh [24]. 
 
Cigarette smoking impacts body weight and composition, peripheral insulin 
sensitivity, and pancreatic β cell function 
Whereas epidemiological studies have tested associations between smoking and 
diabetes development, a number of studies have also investigated mechanistic 
underpinnings of these associations. In aggregate, data from these studies suggest that 
smoking is associated with deleterious changes in body composition, despite being 
linked to reduced body weight [25].  Individuals who smoked >20 cigarettes per day had 
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an adjusted odds ratio for abdominal obesity of 1.93 (95% CI:  1.16 to 3.21) as 
compared to never-smokers [26]. Cross-sectional data from 21,828 men and women 
aged 45 to 79 years in the United Kingdom demonstrated that smokers had higher 
waist-to-hip ratios as compared to non-smokers, and this measure was directly 
correlated with the amount of smoking [27]. Furthermore, in a cross-sectional study of 
513 Japanese men, greater lifetime smoking exhibited a significant and positive 
association with higher waist-to-hip ratio and the visceral adipose to subcutaneous 
adipose ratio, assessed by computerized tomography (CT) scans [25].  These findings 
support the general notion that smoking is linked to adverse fat distribution.  
Interestingly, changes in body composition associated with cigarette smoking appear to 
be driven primarily by nicotine signaling, both centrally and peripherally [reviewed in 
[16]] 
Consistent with these changes in body composition, smoking acutely worsened 
glucose tolerance and the insulin sensitivity index in twenty chronic smokers who had 
paired oral glucose tolerance tests performed after smoking and under control 
conditions [28].  In persons with established diabetes, euglycemic hyperinsulinemic 
clamp analyses revealed that total body glucose disposal was reduced in smokers 
compared to those who did not smoke [29]. In addition, data support a direct effect of 
nicotine on glucose homeostasis.  In this regard, results from hyperglycemic-
hyperinsulinemic clamp analyses performed on subjects with established T2D revealed 
that active smoking as well as acute transdermal nicotine patch administration led to 
decreased insulin action [18].  
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 In addition to the above effects on body composition and peripheral insulin 
signaling, Clinical studies also suggest that smoking impairs measures of β cell function. 
Among 1,199 Japanese men aged 30-79, the incidence of impaired insulin secretion, as 
represented by a change in the insulinogenic index during a 75-gram oral glucose 
tolerance test over a mean follow-up of 2.8 years, was 1.06 in ex-smokers versus 1.95 
in current smokers, as compared to never-smokers.  Furthermore, the number of pack-
years of smoking was found to dose-dependently impair β cell function [30]. Separately, 
Ostgren and colleagues studied nearly 260 Swedish men and found that current 
cigarette smokers had lower β cell function, as measured by the homeostatic model 
assessment method (HOMA-β), compared to never smokers (58.1 vs. 90.1; 95% CI:  
17.8-43.5, p <0.001).  This difference remained significant even after adjustment for 
age, body mass index, alcohol intake, and physical activity.  Interestingly, results from 
this study suggested dichotomous effects by gender, as no significant relationships 
were found between smoking and β cell function among nearly 350 female never and 
current smokers [31].   
 
Molecular mechanisms underlying the development of altered glucose 
homeostasis in smokers 
 To gain insight into the effects of smoking on peripheral insulin signaling, 
Bergman and colleagues analyzed skeletal muscle biopsy specimens from smokers and 
nonsmokers and found that smokers had increased Ser636 phosphorylation of IRS-1, a 
known inhibitory modification with negative effects on insulin sensitivity.  Smokers also 
exhibited decreased expression of peroxisome proliferator-activated receptor-gamma 
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(PPAR-γ), a transcription factor known to promote insulin sensitivity [32].  A later study 
from this same group characterized the in vitro effects of nicotine on skeletal muscle 
cultures and showed that nicotine exposure resulted in increased IRS-1 Ser636 
phosphorylation and activation of mTOR and MAPK signaling, while rapamycin-induced 
inhibition of mTOR was able to reverse nicotine-induced alterations in IRS-1 signaling 
[33].   
Nicotine has also been reported to increase lipolysis from adipose tissue [34] by 
activating AMP-activated protein kinase α2 (AMPKα2) in adipocytes, leading to 
increased phosphorylation and proteosomal degradation of MAP kinase phosphatase-1 
(MKP1). Nicotine-induced reductions in MKP1 resulted in activation of p38 mitogen-
activated protein kinase and c-Jun N-terminal kinase, ultimately promoting IRS-1 
degradation and loss of insulin-mediated inhibition of lipolysis [35].  Consistent with 
these observations, serum triglyceride levels have been shown to be higher in smokers 
compared to nonsmokers [36]. Furthermore, cigarette smoking was independently 
associated with the onset of non-alcoholic fatty liver disease (NAFLD) [37] 
Smoking may also impact insulin sensitivity through additional epigenetic 
mechanisms. Analysis of 432 blood samples from subjects in the Northern Sweden 
Population Health Study revealed that 95 DNA methylation sites within 66 distinct 
chromosomal regions were differentially methylated in smokers. Interestingly, genes 
associated with “insulin receptor binding” and “negative regulation of glucose import” 
were enriched within the dataset, suggesting that smoking-induced diabetes 
susceptibility may arise from aberrant methylation of DNA [38]. In support of this theory, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 Page 9 
a recent paper found that cigarette smoking is associated with altered methylation 
patterns in several previously identified diabetes-related genes [39]  
 In contrast to studies testing molecular associations between smoking and 
reduced insulin sensitivity, considerably less is known about how smoking impacts 
pancreatic β cell function. Nicotinic receptors have been reported on pre-synaptic 
sympathetic nerve terminals and postsynaptic receptors within islets, while nicotinic 
receptor agonism and antagonism have been shown to modulate insulin secretion.  
Stagner and Samols performed a series of experiments using an in vitro canine whole 
pancreas perifusion model.  Acutely, perifusion of canine pancreas with nicotine 
resulted in transient stimulation of insulin secretion, which was blocked by ganglionic 
postsynaptic nicotinic receptor blockade using alpha-bungarotoxin. Interestingly, pre-
synaptic receptor blockade also led to decreased insulin secretion [40]. However, in 
another study, contrasting effects were observed in isolated rat islets, where insulin 
secretion was increased by alpha-bungarotoxin.  Moreover, nicotine suppressed alpha-
bungarotoxin-induced increase in insulin secretion [41].  In yet another analysis, acute 
nicotine treatment also moderately decreased insulin secretion in human islets, while 
chronic treatment for 48 hrs led to a significant reduction in insulin secretion [42].  Some 
of these discrepancies may be related to species-related differences as well as 
differences between experiments performed using a pancreas perifusion system and 
isolated islets. However, available data fail to provide clarity regarding the effects of 
nicotine on normal pancreatic β cell function.  As such, additional mechanistic studies 
are warranted to more completely understand the physiology of nicotinic signaling in the 
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islet as well as the clinical association between smoking and reduced β cell function [30, 
31].    
Not withstanding these uncertainties, smoking and nicotine exposure may  
induce a pro-inflammatory metabolic state that would be expected to impact both insulin 
sensitivity and β cell function.  Nicotine has been shown to decrease activity of free 
radical scavenging enzymes, in turn increasing generation of hydroxyl free radicals by 
increased superoxide anion and hydrogen peroxide [43]. Furthermore, skeletal muscle 
expression of monocyte chemotactic protein-1 was increased in smokers compared to 
non-smokers [32].  In healthy middle-aged non-obese men, long-term nicotine gum 
chewers (NGCs) had greater plasminogen activator inhibitor-1 activity compared to non-
smoking controls [36]. Smoking also causes an endogenous stress response 
characterized by increased circulating levels of cortisol, catecholamines, and growth 
hormone that can impact glucose homeostasis at both the level of the β cell function 
and peripheral tissues [44, 45].   
 
Alternative smoking products and T2D risk 
Of note, the increased risk for T2D development associated with tobacco use 
may not be limited only to cigarette smoking. There is evidence to suggest that heavy 
use of alternative smoking products, including smokeless tobacco (oral moist snuff, 
“snus”), may also impact diabetes development [46, 47]. A prospective population 
based study of Swedish men demonstrated an increased risk for the development of 
T2D in individuals who used >5 boxes of snus per week (odds ratio: 3.3, CI 1.4-8.1) 
[47].  In a second study, also performed in Sweden, high consumption of smokeless 
tobacco (“snus”) predicted an increased risk of type 2 diabetes in a 10-year prospective 
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study of middle-aged men. In contrast, another Swedish study failed to find an 
association between snus use and T2D [48].  However, more recently a pooled analysis 
from five cohorts revealed a hazard ratio of incident type 2 diabetes of 1.15 (95% CI: 
1.00-1.32) in current users of snus compared to never users.  Moreover, risk increased 
with heavier weekly use [49].  In aggregate, these findings appear to support an 
increased risk of diabetes with smokeless tobacoo at least in the the Swedish 
population, but further studies are needed to determine how applicable these findings 
are to other populations and ethnic groups.  
 
Developmental effects of smoking 
Smoking during pregnancy is associated with an increased risk of gestational 
diabetes mellitus (adjusted odds ratio = 1.9, 95% CI: 1.0, 3.6) [50].  Moreover, the 
incidence of diabetes in offspring may be affected by exposure to smoke in utero. For 
example, the 1958 British Birth Cohort study measured Hb1Ac levels in participants at 
age 45, and observed that maternal smoking was associated with an increase in the 
prevalence of HbA1C >6% and development of T2D in adulthood [51].  Likewise, data 
from 34,453 participants in the Nurses’ Health Study II revealed that maternal (and to a 
lesser extent, paternal) smoking during the first trimester was an independent risk factor 
for the development of T2D in offspring, even after adjusting for confounders such as 
birth weight and later-life BMI (hazard ratio 1.34, 9% CI 1.01-1.76) [52]. Analysis from 
the Prospective Singleton Pregnancy Cohort showed slightly higher proinsulin-to-insulin 
ratios in offspring of smokers compared to nonsmokers, suggesting alterations in 
pancreatic β cell function and potentially increased β cell stress at birth (35). Finally, 
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offspring of rats exposed to nicotine exhibited altered insulin biosynthesis, β cell 
degranulation, increased islet oxidative stress, and impaired glucose-stimulated insulin 
secretion, all of which were preceded by the appearance of mitochondrial structural 
abnormalities [53]. Furthermore, exposure to secondhand (passive) cigarette smoke 
after the prenatal period is also linked to an increased risk for T2D development. A 
recent meta-analysis of prospective studies including almost 6 million individuals 
reported a 22% increase in the risk for development of T2D in those never smokers 
exposed to passive smoke compared to never smokers not exposed to passive smoke 
[54] 
 
Smoking Cessation and Glucose Homeostasis 
Active smoking has been associated with reduced appetite and weight loss.  On 
the other hand, smoking cessation is often associated with weight gain.  In some 
studies, cessation of cigarette smoking has also been linked to increased incidence of 
T2D, likely due to increased weight gain upon withdrawl of nicotine, and this increased 
risk of T2D was highest in the first 3 years post-cessation [55]. Previous studies have 
suggested significant heterogeneity in the magnitude of weight gain following smoking 
cessation, with the greatest weight gain often seen in individuals with the highest daily 
cigarette consumption [56].  Studies of gender-related differences in post-cessation 
weight gain (PCWG) have yielded conflicting results, with some studies showing greater 
weight gain in men and others showing higher weight gain in women [57, 58].  Self-
report data from the NHANES study revealed an average PCWG of approximately 1.4 
kg (95% CI: 0.8 to 2.0) in recent quitters who had stopped smoking within the past year. 
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In this study, normal and overweight individuals were at greatest risk of weight gain, 
while obese individuals tended to lose a small but insignificant amount of weight [59].  
Mean one-year weight gain in another sedentary group of smokers was documented to 
be between 3.3-3.9 kg [57]. While the effects of smoking cessation on glucose 
homeostasis may be often confounded by the presence of weight gain, at least one 
study has shown that prior to any change in weight, short-term smoking cessation of 1-2 
weeks was sufficient to reverse defects in insulin sensitivity and skeletal muscle insulin 
signaling in both male and female young adults [33].  Longer term studies are needed to 
define how these parameters change over time.    
Varenicline is a partial nicotine receptor agonist that has been shown to promote 
smoking cessation, with abstinence rates up to two- or three-fold higher compared with 
non-pharmacological means.  Similarly, buproprion, an anti-depressant, and nicotine 
replacement therapy via a patch or gum have been shown to be more efficacious in 
promoting abstinence compared to placebo treatment [60]. A Cochrane systematic 
review suggested that personalized weight support and counseling may successfully 
reduce post-cessation weight gain. Buproprion, varenicline, and nicotine replacement 
therapy have also been shown attenuate weight gain acutely during active treatment; 
yet it is unclear whether such therapies can help control weight in the long term [61].  
Moreover, given studies suggesting an independent effect of nicotine to perturb glucose 
homeostasis, it remains to be clarified whether cessation strategies that include nicotine 
agonists differentially impact long-term changes in glucose homeostasis. Interestingly, 
in vitro treatment of INS-1 β cells with nicotine, varenicline, and bupropion led to 
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decreased levels of glucose-stimulated insulin secretion with each agent, suggesting 
that further studies to address these questions are needed [62]. 
The clear association between T2D risk and disease severity underscore the 
importance of promoting smoking cessation in indvidiuals with T2D. However, many 
persons with T2D continue to smoke, despite these contraindications. Increasing rodent 
and human evidence indicates that T2D may increase the rewarding effects of 
dopamine, as disrupted insulin signaling during T2D suppresses dopamine signaling in 
the mesolimbic reward pathway [63].   
 
 
Conclusions 
 
Epidemiological studies demonstrate a clear association between cigarette 
smoking and an increased risk of T2D, whereas clinical data suggest an effect of 
smoking and nicotine on body composition, insulin sensitivity, and pancreatic β cell 
function. Human, rodent, and in vitro studies have begun to yield insight into the 
molecular mechanisms through which nicotine and smoking exposure impact glucose 
homeostasis.  However, a complete understanding of the underlying pathways impacted 
by tobacco abuse, especially mechanistic studies focused on the pancreatic β cell, are 
lacking. Not withstanding these unknowns, this comprehensive review of available 
literature suggests that smoking should be elevated to the category of a recognized and 
modifiable risk factor for the development of diabetes, uniformly across all diabetes 
organizations and that smoking status should be considered as an indication for 
diabetes screening.  Moreover, smoking cessation along with weight control post 
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cessation should be promoted as an essential public health practice for diabetes 
prevention.  
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